Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ADH5 | P11766 | 1/20 | 0.67 |
| ▸ | RPA1 | P27694 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934990 | 0.85 | TP53 (0.74) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL20539688 | 0.85 | TP53 (0.74) | TP53NPC1RAB9ANPSR1ADH5 | |
| Hydrochloric Acid SCHEMBL4449070 | 0.84 | TP53 (0.72) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL9984638 | 0.83 | ADH5 (0.95) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL17204982 | 0.82 | ADH5 (0.76) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL21983385 | 0.82 | TP53 (0.70) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL21880317 | 0.80 | TP53 (0.66) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL21983540 | 0.80 | TP53 (0.66) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL5379467 | 0.80 | NPC1 (0.64) | TP53NPC1RAB9ANPSR1ADH5 | |
| SCHEMBL10053604 | 0.79 | NPC1 (0.65) | TP53NPC1RAB9ANPSR1ADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-2942346-B1 | PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-8063082-B2 | E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063082-B2 | E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063082-B2 | E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080132548-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | disclosed |
| US-20080132548-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | disclosed |
| US-20080132548-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | TP53 974/4885NPC1 2177/4885RAB9A 1958/4885 |
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | TP53 3284/4885NPC1 287/4885RAB9A 2980/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | TP53 275/4885NPC1 868/4885RAB9A 35/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | TP53 437/4885NPC1 3320/4885RAB9A 2597/4885 |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | TP53 3284/4885NPC1 287/4885RAB9A 2980/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | TP53 3284/4885NPC1 287/4885RAB9A 2980/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | TP53 1344/4885NPC1 403/4885RAB9A 31/4885 |
| US-20080132548-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | TP53 2206/4885NPC1 4684/4885RAB9A 2065/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | TP53 3284/4885NPC1 287/4885RAB9A 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.